Authored by: Will Reese, Chief Innovation Officer at Inizio Evoke and Matt Lewis, Global Chief Artificial and Augmented Intelligence Officer at Inizio Medical
President Biden’s 2023 Executive Order1 captures the need to take robust action to tackle some of the risks associated with AI technology. It contains several industry-specific recommendations for healthcare, these include a focus on healthcare data quality, as well as using AI to improve the safety of healthcare workers and patients, various equity considerations, and the use of AI in local settings.
One of the most striking requirements is the creation of a strategic plan for AI use in health and human services, including regulatory implications and additional policy recommendations. In June 2023, the European Union announced the introduction of the AI Act2, creating the world’s first comprehensive AI law, shortly followed by the Cyberspace Administration of China guidelines. As legislations are developed and enacted in the US3, the guidelines specified in the Executive Order remain important. They provide a clear statement of the US Government’s position on AI security issues for the first time, setting out a clear roadmap and direction of travel.
The US Department of Health and Human Services will play an important role in tracking strategic plan updates based on the Executive Order to assess its ongoing implications from an AI perspective. While the Executive Order sets out a broad national framework on these issues, sector-specific higher-level consideration will still be required to translate its principles into insights relevant to their respective industries.
One of the core ethical issues in the use of AI in pharma and healthcare is the ability to verify that information is accurate and from a reputable source…
To read the entire article from Matt Lewis and Will Reese, download our latest AI report.
Sources:
In today’s rapidly evolving healthcare landscape, innovative partnerships are crucial to overcoming key brand challenges and driving measurable impact
Read moreHarness the collective expertise of our biotech experts to maximize the value of your asset across every step of your journey to commercialization.
Read moreMany pharma employees reported that if these challenges are addressed, a congress is far more likely to be successful.
Read more